Arginase I Polyclonal Antibody

Rabbit Anti-Arginase I Polyclonal Antibody

Product Specifications

Background

Arginase catalyzes the hydrolysis of arginine to ornithine and urea. At least two isoforms of mammalian arginase exist (types I and II) which differ in their tissue distribution, subcellular localization, immunologic crossreactivity and physiologic function. The type I isoform encoded by ARG1, is a cytosolic enzyme and expressed predominantly in the liver as a component of the urea cycle. Inherited deficiency of this enzyme results in argininemia, an autosomal recessive disorder characterized by hyperammonemia. Two transcript variants encoding different isoforms have been found for this gene.

CAS Number

9007-83-4

Product Name Alternative

ARG1; Arginase-1; Liver-type arginase; Type I arginase

Gene ID

383

Accession Number

P05089

Reactivity

Human, Mouse, Rat

Immunogen

Synthesized peptide derived from the Internal region of human Arginase I at AA rangle: 30-110

Clonality

Polyclonal

Tag

Arginase-1

Applications

WB, IHC, IF, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

35kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

Arginase I Polyclonal Antibody detects endogenous levels of Arginase I protein.

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC: 100-300; WB 1:500-1:2000; ELISA 1:5000; IF 1:50-200